NCT07843797Recruiting
SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel Occlusions
SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel Occlusions - Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
Patients with acute ischemic stroke caused by distal or medium vessel occlusions (MeVOs) may experience significant disability despite receiving the current standard medical treatment. Although endovascular treatment (EVT) is an established therapy for large vessel occlusions, its benefit in MeVO stroke remains uncertain. The SAIL-MEVO trial is a prospective, multicenter, randomized controlled trial designed to evaluate whether EVT combined with best medical therapy improves functional outcomes compared with best medical therapy alone in selected patients with acute ischemic stroke due to MeVO. Eligible participants will be randomized in a 1:1 ratio to receive either best medical therapy alone or best medical therapy plus EVT using a standardized stepwise approach consisting of aspiration thrombectomy (ADAPT) followed, when necessary, by the SAIL technique (stent retriever-assisted intra-arterial lysis). The primary objective is to determine whether EVT increases the proportion of patients achieving functional independence (modified Rankin Scale score 0-2) at 90 days after stroke. Secondary objectives include assessment of neurological recovery, infarct volume, quality of life, patient-reported outcomes, safety, and procedural outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 420 (estimated)
- First submitted
- 16 Jul 2026
- Start date
- Nov 2026
- Primary completion date
- Jan 2029
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Diseases
- Stroke
- NCT number
- NCT07843797
What you commit to
- Study type: Interventional
- Planned participants: 420
- From Nov 2026 to the primary completion date, Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Intracranial hemorrhage at baseline imaging.
- Severe allergy to iodinated contrast media.
Other
- Proximal large vessel occlusion (internal carotid artery or M1 segment) or tandem cervical internal carotid artery stenosis \>70%.
- Pregnancy.
- Life expectancy less than 3 months.
Who the study is looking for
- Age 18 to 80 years.
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Baseline NIH Stroke Scale (NIHSS) score between 9 and 17.
- Symptom onset to randomization less than 12 hours.
- Acute ischemic stroke due to an isolated medium/distal vessel occlusion involving a non-dominant M2-M3 middle cerebral artery, A2-A3 anterior cerebral artery, or P2-P3 posterior cerebral artery confirmed by CTA or MRA.
- Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on non-contrast CT AND AI-predicted infarct core volume \<10 mL on non-contrast CT (when available) AND AI-defined Tmax \>6s volumen \>30cc on CTP (when available).
- Written informed consent obtained from the participant or a legally authorized representative in accordance with local regulations.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.